Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Iovance Biotherapeutics (IOVA) Gross Margin (2023 - 2025)

Iovance Biotherapeutics (IOVA) has disclosed Gross Margin for 3 consecutive years, with 67.38% as the latest value for Q4 2025.

  • On a quarterly basis, Gross Margin fell 127.0% to 67.38% in Q4 2025 year-over-year; TTM through Dec 2025 was 34.28%, a 889.0% decrease, with the full-year FY2025 number at 34.28%, down 889.0% from a year prior.
  • Gross Margin was 67.38% for Q4 2025 at Iovance Biotherapeutics, up from 42.96% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 1211.41% in Q4 2023 to a low of 915.52% in Q1 2024.
  • A 3-year average of 30.05% and a median of 24.22% in 2025 define the central range for Gross Margin.
  • Peak YoY movement for Gross Margin: tumbled -114276bps in 2024, then skyrocketed 91468bps in 2025.
  • Iovance Biotherapeutics' Gross Margin stood at 1211.41% in 2023, then tumbled by -94bps to 68.65% in 2024, then dropped by -2bps to 67.38% in 2025.
  • Per Business Quant, the three most recent readings for IOVA's Gross Margin are 67.38% (Q4 2025), 42.96% (Q3 2025), and 5.48% (Q2 2025).